-+ 0.00%
-+ 0.00%
-+ 0.00%

UCB RECEIVES U.S. FDA BREAKTHROUGH THERAPY DESIGNATION FOR CIMZIA®(CERTOLIZUMAB PEGOL) IN PREGNANT WOMEN WITH ANTIPHOSPHOLIPID SYNDROME (APS)

Reuters·09/09/2026 12:00:10

Please log in to view news